ArticleScientific reports2025
S-allyl cysteine and alliin enhance catalase activity and prevent aggregation to counter oxidative stress in alzheimer's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oxidative stress is a key driver of Alzheimer's disease (AD), often linked to reduced activity of catalase, a major antioxidant enzyme. In AD, catalase is not only less active but also found as part of harmful protein aggregates with amyloid-β in brain plaques. Finding safe molecules that can boost catalase activity and stop it from aggregating could, therefore, offer a new strategy to lower disease progression. In this study, we examined two natural organosulfur compounds from garlic-S-allyl cysteine (SAC) and Alliin-for their effects on catalase. We found that both compounds significantly increased catalase activity in a concentration-dependent manner by stabilizing its structure and enhancing its thermodynamic stability. Furthermore, Molecular docking and Simulation studies revealed that SAC and Alliin bind at an allosteric site, promoting structural compaction and enhancing stability. Importantly, these compounds also reduced the tendency of catalase to form amyloid-like aggregates, a feature directly relevant to AD pathology. Our findings provide new mechanistic insights into how SAC and Alliin act on catalase-both stabilizing the enzyme and resulting in an increase in its activity along with lowering its aggregation propensity. This suggests that SAC and Alliin may serve as promising, natural candidates for therapeutic intervention in Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.